SCHEMBL24087958

SCHEMBL24087958

N#Cc1c(-c2cccs2)cc(=O)[nH]c1SCc1cccc(Cc2nc(=O)o[nH]2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACMSD Q8TDX5 8/20 0.46
▸ NPSR1 Q6W5P4 5/20 0.41
▸ KDM4E B2RXH2 5/20 0.41
▸ MAPT P10636 5/20 0.41
▸ MEN1 O00255 4/20 0.41
▸ KMT2A Q03164 4/20 0.41
▸ ALDH1A1 P00352 4/20 0.41
▸ HPGD P15428 3/20 0.41
▸ TP53 P04637 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ RXFP1 Q9HBX9 2/20 0.40
▸ L3MBTL1 Q9Y468 2/20 0.40
▸ USP2 O75604 1/20 0.40
▸ PRNP P04156 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ PKM P14618 1/20 0.40
▸ BLM P54132 1/20 0.40
▸ SAE1 Q9UBE0 1/20 0.40
▸ UBA2 Q9UBT2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24087881 0.89 KDM4E (0.45) ACMSDNPSR1KDM4EMAPTMEN1
SCHEMBL24087930 0.87 ACMSD (0.49) ACMSDNPSR1KDM4EMAPTMEN1
SCHEMBL26847362 0.83 ACMSD (0.44) ACMSDNPSR1KDM4EMAPTMEN1
SCHEMBL24088040 0.83 ACMSD (0.44) ACMSDNPSR1KDM4EMAPTMEN1
SCHEMBL26847199 0.81 ACMSD (0.48) ACMSDNPSR1KDM4EMAPTMEN1
SCHEMBL24087894 0.81 KDM4E (0.48) ACMSDNPSR1KDM4EMAPTMEN1
SCHEMBL24088014 0.80 ACMSD (0.68) ACMSDNPSR1KDM4EMAPTMEN1
SCHEMBL26847347 0.80 ACMSD (0.42) ACMSDNPSR1KDM4EMAPTMEN1
SCHEMBL23850235 0.79 ACMSD (0.64) ACMSDNPSR1KDM4EMAPTMEN1
SCHEMBL20339975 0.77 ACMSD (0.64) ACMSDKDM4EKMT2AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230381177-A1 INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE TES PHARMA S.R.L. (IT) 2023-11-30 — — US disclosed
US-20210379069-A1 INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE TES PHARMA S R L (IT) 2021-12-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230381177-A1 INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE ACMSD, GLS, ALDH7A1 ACMSD 1/4885NPSR1 2669/4885KDM4E 1110/4885
US-20210379069-A1 INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE ACMSD, GLS, ALDH7A1 ACMSD 1/4885NPSR1 2669/4885KDM4E 1110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback